<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399007</url>
  </required_header>
  <id_info>
    <org_study_id>DPS-201301</org_study_id>
    <nct_id>NCT02399007</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China</brief_title>
  <official_title>A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Hip Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Medical (Suzhou) Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Medical (Suzhou) Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial of total Hip system used in Primary Total Hip Arthroplasty in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary&#xD;
      Total Hip Arthroplasty Devices Manufactured in China versus Devices Manufactured Outside of&#xD;
      China&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2015</start_date>
  <completion_date type="Actual">January 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 4, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Harris Hip Total Score at 12 months postoperatively</measure>
    <time_frame>12 months postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>One year non-revision rate where revision is defined as removal of any component for any reason with the exception of infection</measure>
    <time_frame>12 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year non-revision rate where revision is defined as removal of any component secondary to infection</measure>
    <time_frame>12 months postoperatively</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Harris Hip Total Score success: success is ≥ 80 points.</measure>
    <time_frame>12 months postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>Preoperation to 12 months postoperatively</time_frame>
    <description>SF 12: scores at 1 yr, change from pre-op. WOMAC: scores at 1 yr., change from pre-op.</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiographs: incidence of clinically relevant radiolucent lines, and osteolysis</measure>
    <time_frame>Preoperation to 12 months postoperatively</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events: tally the type and frequency of adverse events</measure>
    <time_frame>Preoperation to 12 months postoperatively</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Congenital Hip Dysplasia</condition>
  <condition>Avascular Necrosis</condition>
  <arm_group>
    <arm_group_label>Total Hip System made in China</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Hip System made outside of China</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)</intervention_name>
    <description>SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)</description>
    <arm_group_label>Total Hip System made in China</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)</intervention_name>
    <description>Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)</description>
    <arm_group_label>Total Hip System made outside of China</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is ≥55, and ≤80 years old&#xD;
&#xD;
          2. The Subject must be of Chinese ethnic descent and be willing to return on three&#xD;
             occasions for clinical evaluations.&#xD;
&#xD;
          3. Subject is a suitable candidate for primary total hip replacement using the devices&#xD;
             described in this CIP&#xD;
&#xD;
          4. Subject must meet all criteria specified in BOTH SUN hip stem and Summit hip stem&#xD;
             instructions for use (IFU)&#xD;
&#xD;
          5. Before surgery, subject is willing and able to sign the informed consent form approved&#xD;
             by the Institutional Review Board (IRB), Ethics Committee (EC) or Ethical Review Board&#xD;
             (ERB).&#xD;
&#xD;
          6. Subject, in the opinion of the Clinical Investigator, is able to understand this&#xD;
             clinical investigation and co-operate with investigational procedures.&#xD;
&#xD;
          7. Subject must be comfortable with speaking, reading, and understanding questions and&#xD;
             providing responses in an available translated language for the patient reported&#xD;
             outcomes (PROs) in the CIP.&#xD;
&#xD;
          8. Subject is receiving a unilateral hip replacement or, if a contralateral hip&#xD;
             replacement is anticipated, the surgery must occur within 6 months of the first study&#xD;
             hip. The second hip will not be enrolled in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject does not provide written voluntary consent to participate in the clinical&#xD;
             study.&#xD;
&#xD;
          2. The Subject is a woman who is pregnant or lactating.&#xD;
&#xD;
          3. Subjects who have undergone THA in contralateral hip within the past 6 months.&#xD;
&#xD;
          4. Contralateral hip has been enrolled in the study.&#xD;
&#xD;
          5. Presence of any previous prosthetic hip replacement device in affected hip.&#xD;
&#xD;
          6. Previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the&#xD;
             affected hip&#xD;
&#xD;
          7. Subject has hip dysplasia CROWE classification grade of 3 or 4.&#xD;
&#xD;
          8. Above knee amputation of either contralateral or ipsilateral leg&#xD;
&#xD;
          9. Subject is anticipated to require a contralateral THA between 6 months and 1-year.&#xD;
&#xD;
         10. Subject has an active infection&#xD;
&#xD;
         11. Subject has a malignant disease, severe condition, alcohol or drug addiction and/or&#xD;
             mental disorders that the investigator believes will interfere with the study&#xD;
             participation.&#xD;
&#xD;
         12. Subjects with severe osteoporosis, metabolic bone disease, radioactive bone disease or&#xD;
             tumor in the bone surrounding the hip joint that, in the opinion of the investigator,&#xD;
             will negatively impact implant fixation and the outcome of the investigation;&#xD;
&#xD;
         13. Subject has significant neurological or musculoskeletal disorders or disease that may&#xD;
             adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis,&#xD;
             cerebral infarction, hemiplegia, Charcot disease).&#xD;
&#xD;
         14. Subject is not comfortable with speaking, reading, and understanding questions and&#xD;
             providing responses in an available translated language for the PROs in the CIP.&#xD;
&#xD;
         15. Subject has a medical condition with less than 2 years of life expectancy due to other&#xD;
             medical conditions.&#xD;
&#xD;
         16. The patient has comorbid condition(s) that could limit the patient's ability to&#xD;
             participate in the study, compliance with follow-up requirements or impact the&#xD;
             scientific integrity of the study.&#xD;
&#xD;
         17. The patient is currently participating in another investigational drug or device&#xD;
             study.&#xD;
&#xD;
         18. Subject is a prisoner.&#xD;
&#xD;
         19. Subject has a known allergy to any component of the implant (metal for example).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shigui Yan</last_name>
    <role>Principal Investigator</role>
    <affiliation>The second Affiliated Hospital of Zhejiang Medicine University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The first affiliated hospital of Guangzhou Tranditional Meidical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The third affiliated hospital of Hebei University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second affiiliated hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The affiliated hosoital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medicine University</name>
      <address>
        <city>Hohhot</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The general hospital of Kunming</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second Affiliated Hospital of Zhejiang Medicine University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Dislocation</mesh_term>
    <mesh_term>Developmental Dysplasia of the Hip</mesh_term>
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

